TP53, a tumor suppressor gene, is mutated in 40–50% of lung cancer patients but portrays an unclear relationship: though many studies observed a worse prognosis in lung cancer patients with a TP53 mutation, others indicated no significant impact on survival [8,10]. The gene discussed is TP53; the disease is lung cancer.